E1	Condition:T1 Name:T2 Severity:T33
E3	Procedure:T3 Name:T4 Temporality:E21
E5	Procedure:T5 Name:T6
E8	Condition:T8 Name:T9 Severity:T53
E10	Procedure:T10 Name:T11
E13	Eq-Comparison:T21 Operator:T14 Value:T18 Temporal-Unit:T31
E14	Eq-Comparison:T22 Operator:T16 Value:T20 Unit:T58 Per:T59
E15	Eq-Comparison:T23 Temporal-Period:T24
E16	Eq-Comparison:T25 Temporal-Period:T26 Value:T19 Temporal-Unit:T17
E2	Study:T27 Study-Of:E5
E4	Assertion:T28 Asserted:E5
E6	Or:T30 Arg:T7 Arg2:T29
E7	Age:T32 Eq-Comparison:E13
E9	Eq-Comparison:T35 Value:T34 Value2:T33 Operator:T36
E11	Condition:T37 Name:T38 Temporality:E15 Temporality2:E16
E17	And:T39 Arg:E1 Arg2:E11
E18	Procedure:T15 Name:T40
E19	Indication:T41 Indication-For:E3
E20	Study:T42
E21	Eq-Comparison:T43 Temporal-Period:T44
E22	Temporal-Connection:T45 Arg:E21 Arg2:E20
E23	And:T46 Arg:E11 Arg2:E3
E24	Assertion:T47 Asserted:E10
E12	Drug:T12 Name:T13
E25	Assertion:T48 Asserted:E12
E26	And:T49 Arg:E24 Arg2:E25
E27	Modifier:T50 Modifies:T52
E28	Condition:T51 Name:T52
E29	Observation:T54 Name:T55
E30	Observation:T56 Name:T57 Eq-Comparison:E14
E31	Condition:T60
E32	Condition:T61 Name:T62
E33	Risk:T63 Risk-For:E32 Polarity:T64
E34	Allergy:T65 Name:E35 Name2:E37
E35	Drug:T67 Name:T66
E36	Or:T68 Arg:E35 Arg2:E37
E37	Drug:T69 Name:T70
T1	Condition 256 271	mitral stenosis
T2	Condition-Name 256 271	mitral stenosis
T3	Procedure 391 406	anticoagulation
T4	Procedure-Name 391 406	anticoagulation
T5	Procedure 126 136	procedures
T6	Procedure-Name 126 136	procedures
T8	Condition 606 623	renal dysfunction
T9	Condition-Name 606 623	renal dysfunction
T10	Procedure 484 499	oral medication
T11	Procedure-Name 484 499	oral medication
T14	Eq-Operator 203 204	≥
T16	Eq-Operator 653 654	<
T17	Eq-Temporal-Unit 370 376	months
T18	Eq-Value 205 207	18
T19	Eq-Value 367 369	12
T20	Eq-Value 654 656	15
T21	Eq-Comparison 203 216	≥ 18 year-old
T22	Eq-Comparison 653 663	<15 mL/min
T23	Eq-Comparison 283 290	history
T24	Eq-Temporal-Period 283 290	history
T25	Eq-Comparison 361 376	prior 12 months
T26	Eq-Temporal-Period 361 366	prior
T27	Study 120 125	study
T28	Assertion 89 100	willingness
T7	Life-Stage-And-Gender 189 192	Men
T29	Life-Stage-And-Gender 197 202	women
T30	Or 193 196	and
T31	Eq-Temporal-Unit 208 212	year
T32	Age 213 216	old
T33	Severity 249 255	severe
T34	Severity 237 245	moderate
T35	Eq-Comparison 237 255	moderate to severe
T36	Eq-Operator 246 248	to
T37	Condition 294 296	AF
T38	Condition-Name 294 296	AF
T39	And 272 275	who
T15	Procedure 331 349	electrical tracing
T40	Procedure-Name 331 349	electrical tracing
T41	Indication 410 419	indicated
T42	Study 456 461	study
T43	Eq-Comparison 424 435	planned for
T44	Eq-Temporal-Period 424 435	planned for
T45	Temporal-Connection 440 448	duration
T46	And 377 380	and
T47	Assertion 468 478	Ability to
T12	Drug 532 543	rivaroxaban
T13	Drug-Name 532 543	rivaroxaban
T48	Assertion 507 517	willing to
T49	And 500 503	and
T50	Modifier 577 588	Left atrial
T51	Condition 589 593	clot
T52	Condition-Name 589 593	clot
T53	Severity 599 605	Severe
T54	Observation 625 645	creatinine clearance
T55	Observation-Name 625 645	creatinine clearance
T56	Observation 647 651	CrCl
T57	Observation-Name 647 651	CrCl
T58	Eq-Unit 657 659	mL
T59	Eq-Temporal-Unit 660 663	min
T60	Condition 687 696	condition
T61	Condition 728 736	bleeding
T62	Condition-Name 728 736	bleeding
T63	Risk 720 724	risk
T64	Polarity 715 719	high
T65	Allergy 742 750	Allergic
T66	Drug-Name 754 764	rivaroxabn
T67	Drug 754 764	rivaroxabn
T68	Or 764 765	/
T69	Drug 765 773	warfarin
T70	Drug-Name 765 773	warfarin
A1	Eq-Operator-Value T14 GTEQ
A3	Eq-Operator-Value T16 LT
A4	Eq-Temporal-Unit-Value T17 month
A5	Eq-Temporal-Period-Value T24 past
A6	Eq-Temporal-Period-Value T26 past
A7	Assertion-Type-Value E4 hypothetical
A8	Life-Stage-And-Gender-Type T7 male
A9	Life-Stage-And-Gender-Type T29 female
A10	Eq-Temporal-Unit-Value T31 year
A11	Severity-Value T33 severe
A12	Severity-Value T34 moderate
A13	Eq-Operator-Value T36 BETWEEN
A2	Eq-Temporal-Period-Value T44 future
A14	Temporal-Connection-Type-Value E22 during
A15	Assertion-Type-Value E24 hypothetical
A16	Assertion-Type-Value E25 hypothetical
A17	Severity-Value T53 severe
A18	Observation-Type-Value T55 lab
A19	Eq-Temporal-Unit-Value T59 minute
A20	Polarity-Value T64 high
R1	Found-By Arg1:E11 Arg2:E18
R2	Abbrev-Of Arg1:E30 Arg2:E29
R3	Caused-By Arg1:E33 Arg2:E31